Safely and well informed

Company profile

Business description

HAEMATO froup is active in the pharmaceutical sector as a manufacturer and wholesaler. The focus of its business activities is on innovative therapies and the expansion of business in the lifestyle and aesthetics sector. In the area of innovative therapies, HAEMATO specialises in five major therapeutic areas with its product portfolio: oncology, rheumatology, neurology, HIV/AIDS and ophthalmology. Furthermore, privately financed products for aesthetic treatments are also part of the portfolio.  

Company Information

First trading day
10.05.1993

Accounting standard
HGB / IFRS

End of financial year
31.12.

Management Board
Patrick Brenske

Supervisory Board
Andrea Grosse, Chairwoman of the Supervisory Board
Prof. Dr. Dr. Sabine Meck, Deputy Chairwoman of the Supervisory Board
Uwe Zimdars, Member of the Supervisory Board

Key financial figures

The most important key figures at a glance (in TEUR)

 
2020
2019
2018
2015
2010
Balance sheet total 169.058 128.567 116.516 106.989 36.541
Equity 125.480 72.218 75.676 58.289 12.323
Equity ratio 74,2 % 56,2 % 64,9 % 54,5 % 34 %
Sales revenue 238.333 197.834 274.120 229.727 6.958
EBIT 1.627 -19 8.503 8.223 1.569
Net profit for the year -4.831 -1.172 6.276 5.540 1.579
Balance sheet profit 22.256 27.086 30.544 24.646 2.423

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us